Prevalence and molecular characterizations of seven additional drug resistance among multidrug-resistant tuberculosis in China: a subsequent study of a national survey

Multidrug-resistant tuberculosis (MDR-TB), defined as resistance to at least isoniazid (INH) and rifampicin (RIF), is a major threat to TB control and prevention strategy worldwide.1 Compared with drug-susceptible TB, treatment of MDR-TB requires longer time and more expensive drugs with greater toxicities. 2 The World Health Organization (WHO) recommended key changes to treat multidrug- and RIF-resistant tuberculosis (MDR/RR-TB) in August 2018, 3 and categorized levofloxacin/moxifloxacin (Mfx), bedaquiline (Bdq) and linezolid (Lzd) as Group A (medicines to be prioritized), clofazimine (Cfz), cycloserine (Cs)/terizidone as Group B (medicines to be added next), and ethambutol, delamanid (Dlm), pyrazinamide (PZA), imipenem-cilastatin, meropenem, amikacin/streptomycin, thionamide/prothionamide, p-aminosalicylic acid as Group C (medicines to be included to complete the regimens and when agents from Groups A and B cannot be used) based on the latest evidences after balancing between effectiveness and safety.
Source: Journal of Infection - Category: Infectious Diseases Authors: Source Type: research